Login to Your Account

BIO InvestorForum

CTI Plans Zevalin s Revival; Satraplatin Wait Soon Over

By Randall Osborne

Monday, October 15, 2007
SAN FRANCISCO Remember Zevalin? The once-trumpeted radioactive immune therapy for non-Hodgkin s lymphoma from IDEC Pharmaceuticals Inc. (now Biogen Idec Inc.) won approval in February 2002. Hopes ran high, with sales projections in the $500 million range, but performance fell short. Biogen Idec reported $18 million in worldwide sales last year, $16.4 million of that amount in the U.S. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription